Evidence map›Paper›PMID 37649020›Full record

ArticleBMC medicine2023

CAR-T cells targeting CD38 and LMP1 exhibit robust antitumour activity against NK/T cell lymphoma.

Hongwen Li, Wenting Song, Jiazhuo Wu, Zhuangzhuang Shi, Yuyang Gao, Jiwei Li, Lijuan Han, Jianxiang Zhang, Zhaoming Li, Yong Li and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Viral oncogenesis in cancer: from mechanisms to therapeutics.Signal transduction and targeted therapy · 2025
    Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Advances in CAR-T-cell therapy in T-cell malignancies.Journal of hematology & oncology · 2024
    Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Hongwen Li *Department of Oncology, Jianshendong Rd., The First Affiliated Hospital of Zhengzhou University, No. 1, Zhengzhou, 450052, Henan Province, China.
Wenting Song *Department of Oncology, Jianshendong Rd., The First Affiliated Hospital of Zhengzhou University, No. 1, Zhengzhou, 450052, Henan Province, China.
Jiazhuo WuDepartment of Oncology, Jianshendong Rd., The First Affiliated Hospital of Zhengzhou University, No. 1, Zhengzhou, 450052, Henan Province, China.
Zhuangzhuang ShiDepartment of Oncology, Jianshendong Rd., The First Affiliated Hospital of Zhengzhou University, No. 1, Zhengzhou, 450052, Henan Province, China.
Yuyang GaoDepartment of Oncology, Jianshendong Rd., The First Affiliated Hospital of Zhengzhou University, No. 1, Zhengzhou, 450052, Henan Province, China.
Jiwei LiDepartment of Oncology, Jianshendong Rd., The First Affiliated Hospital of Zhengzhou University, No. 1, Zhengzhou, 450052, Henan Province, China.
Lijuan HanDepartment of Oncology, Jianshendong Rd., The First Affiliated Hospital of Zhengzhou University, No. 1, Zhengzhou, 450052, Henan Province, China.
Jianxiang ZhangDepartment of Oncology, Jianshendong Rd., The First Affiliated Hospital of Zhengzhou University, No. 1, Zhengzhou, 450052, Henan Province, China.
Zhaoming LiDepartment of Oncology, Jianshendong Rd., The First Affiliated Hospital of Zhengzhou University, No. 1, Zhengzhou, 450052, Henan Province, China.
Yong LiDepartment of Medicine, Baylor College of Medicine, Houston, TX, USA.
Mingzhi ZhangDepartment of Oncology, Jianshendong Rd., The First Affiliated Hospital of Zhengzhou University, No. 1, Zhengzhou, 450052, Henan Province, China. mingzhi_zhang1@163.com.ORCID http://orcid.org/0000-0003-3581-551X
First Affiliated Hospital of Zhengzhou University · CNZhengzhou University · CNBaylor College of Medicine · USHenan Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNatural killer/T cell lymphoma (NKTCL) is an aggressive lymphoma with a poor prognosis. Chimeric antigen receptor-transduced T (CAR-T) cell therapy has become a promising immunotherapeutic strategy against haematologic malignancies.

methodsIn this study, four CAR-T cell lines (CD38-CAR, LMP1-CAR, CD38-LMP1 tandem CAR 1 and CD38-LMP1 tandem CAR 2) were generated. The effect of CAR-T cells against NKTCL cells was evaluated both in vitro and in vivo. Expression of T cell activation markers and cytokines produced by CAR-T cells were detected by flow cytometry.

resultsThe four CAR-T cell lines could effectively eliminate malignant NKTCL cells. They could be activated and produce inflammatory cytokines in a target-dependent manner. In vivo tests showed that the CAR-T cells exhibited significant antitumour effects in a xenotransplanted NKTCL mouse model.

conclusionsIn summary, four CAR-T cell lines exhibited significant cytotoxicity against NKTCL cells both in vitro and in vivo. These results indicated the effective therapeutic promise of CD38 and LMP1 CAR-T cells in NKTCL.

Indexed as

Lymphoma, T-CellReceptors, Chimeric AntigenAnimalsCytokinesDisease Models, AnimalMiceT-LymphocytesCytokinesReceptors, Chimeric AntigenCAR-TCD38ImmunotherapyLMP1NKTCLTandem

Identifiers

PMID37649020
PMCPMC10470138
OpenAlexW4386287096

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.